Clinical trial
A Phase IV, Post-market, Randomized, Controlled, Open-label, Multicenter Clinical Trial Designed to Evaluate the Safety and Effectiveness of MIRRAGEN® Advanced Wound Matrix Plus Standard of Care Compared With Standard of Care Alone in Achieving Complete Wound Closure in Participants With Venous Leg Ulcers by 12 Weeks.
NCT07647705 is registered in ClinicalTrials.gov with ETS Wound Care, LLC as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase IV, Post-market, Randomized, Controlled, Open-label, Multicenter Clinical Trial Designed to Evaluate the Safety and Effectiveness of MIRRAGEN® Advanced Wound Matrix Plus Standard of Care Compared With Standard of Care Alone in Achieving Complete Wound Closure in Participants With Venous Leg Ulcers by 12 Weeks.
- Lead sponsor
- ETS Wound Care, LLC
- Phase
- Not applicable
- Overall status
- Not yet recruiting
- Start date
- July 31, 2026
- Completion date
- January 31, 2028
- Enrollment
- 110 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.
venus leg ulcer, venus leg ulcer (vlu), venus ulcer, vlu